清热化痰方治疗慢性阻塞性肺疾病急性加重期痰热壅肺证26例

Qingrehuatan Prescription for Treating AECOPD Patients with Tanreyongfei Syndrome in 26 Cases

目的探讨清热化痰方对慢性阻塞性肺疾病急性加重期(AECOPD)痰热壅肺证患者临床症状积分及血清因子的影响和疗效分析。方法选取2013年7月至2015年3月医院收治的AECOPD患者54例,按随机数字表法分为试验组26例和对照组24例。两组患者均进行常规基础西医治疗,并给予相同护理。试验组患者在基础治疗上加用清热化痰中药方治疗,两组患者疗程均以10 d为1个疗程。结果治疗后,两组患者临床病症均减轻,临床症状积分显著改善(t=3.50,P<0.05);两组患者血清白细胞介素(IL)-8、IL-4、干扰素(IFN)-γ、肿瘤坏死因子(TNF)-α水平均有所下降,且试验组下降更明显(t=3.67,3.03,4.51,3.89,P<0.05)。结论清热化痰方治疗AECOPD痰热蕴肺证临床疗效明显,能显著改善患者的身体状况和生活质量,其主要作用机制可能是中药成分抑制了体内的炎症因子的产生及作用。

Objective To investigate the clinical symptoms score and the influevce of serum factors of Qingrehuatan Prescription on AECOPD patients with Tanreyongfei Syndrome to analyze its efficacy. Methods 54 cases with AECOPD from July 2013 to March 2015 in the hospital were selected and divided into the experimental group( 26 cases) and the control group( 24 cases) according to the random number table method. All patients were given western medicine on a regular basis,and received the same nursing. Patients in the experimental group were added Qingrehuatan Prescription treatment. The two groups received 1 course for 10 d. Results After treatment,the clinical symptoms of all patients were mitigated,and the clinical symptom scores greatly improved( t = 3. 50,P < 0. 05); the levels of serum IL- 8,IL- 4,IFN- gamma,and TNF- alpha were declined,and the decline in the experimental group was more obvious( t = 3. 67,3. 03,4. 51,3. 89,P < 0. 05). Conclusion Qingrehuatan Prescription in treating AECOPD patients with Tanreyongfei Syndrome has obvious clinical efficacy,can significantly improve the patient  s physical condition and quality of life; its main mechanism is probably the Chinese native medicine ingredient suppressing the production and function of inflammatory markers in the body.